Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara White

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Arthritis and Rheumatism|May 30, 2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell, Andreas Reiff, Olcay Y Jones, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 4, 2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosisJames F Chmiel, Patrick Flume, Damian G Downey, et al.
Clinical Pharmacology and Therapeutics|December 15, 2017
Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute InflammationMadhur P Motwani, Frances Bennett, Paul C Norris, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
The Journal of Investigative Dermatology|May 1, 2022
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical TrialVictoria P Werth, Emily Hejazi, Sandra M Pena, et al.
Orphanet Journal of Rare Diseases|May 25, 2019
Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypesRobert J Pignolo, Geneviève Baujat, Matthew A Brown, et al.
Orphanet Journal of Rare Diseases|May 5, 2019
Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypesRobert J Pignolo, Geneviève Baujat, Matthew A Brown, et al.
Arthritis Research & Therapy|January 5, 2022
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum<sup>TM</sup>Spandana Maddukuri, Jay Patel, De Anna Diaz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2020
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic SclerosisRobert Spiera, Laura Hummers, Lorinda Chung, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Arthritis and Rheumatism|May 30, 2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell, Andreas Reiff, Olcay Y Jones, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 4, 2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosisJames F Chmiel, Patrick Flume, Damian G Downey, et al.
Clinical Pharmacology and Therapeutics|December 15, 2017
Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute InflammationMadhur P Motwani, Frances Bennett, Paul C Norris, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
The Journal of Investigative Dermatology|May 1, 2022
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical TrialVictoria P Werth, Emily Hejazi, Sandra M Pena, et al.
Orphanet Journal of Rare Diseases|May 25, 2019
Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypesRobert J Pignolo, Geneviève Baujat, Matthew A Brown, et al.
Orphanet Journal of Rare Diseases|May 5, 2019
Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypesRobert J Pignolo, Geneviève Baujat, Matthew A Brown, et al.
Arthritis Research & Therapy|January 5, 2022
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum<sup>TM</sup>Spandana Maddukuri, Jay Patel, De Anna Diaz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2020
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic SclerosisRobert Spiera, Laura Hummers, Lorinda Chung, et al.
Pageof 8